GLP-1 Prior Authorization Requirements by Insurer (2026)

GLP-1 prior authorization requirements by insurer do not reduce to one rule per company — and the reason is not that insurers are vague. It is that one insurer can publish several rules at once.

In our July 31, 2026 review of 20 adult Wegovy and Zepbound chronic weight-management pathways in 10 current public policy documents from Cigna, UnitedHealthcare, CVS Caremark, Aetna, and the Blue Cross Blue Shield Federal Employee Program, we found four obesity-alone BMI floors in simultaneous force: 30, 32, 35, and 40. Every pathway required a BMI gate, a lifestyle or weight-management condition, at least 5% weight loss or maintenance for continuation, and a 12-month renewal period. Fourteen of 20 specified a fixed three- or six-month pre-treatment lifestyle period; one of 20 explicitly required trials of two oral weight-management drugs; initial approvals ranged from five to eight months.

“BMI 30, or 27 with a comorbidity” is common in this sample. It is not the rule. Eleven of 20 pathways used a BMI-30 floor, while nine did not.

Cigna alone publishes three current threshold families — IP0206, BEO005, and BEO006 — all effective June 1, 2026, with obesity-alone floors of 30, 32, and 35 for the Wegovy and Zepbound branches reviewed here. UnitedHealthcare’s single current weight-loss document contains a BMI-30 general pathway and a BMI-40 North Dakota fully insured Essential Health Benefits pathway. Both of Cigna’s benefit-exclusion override policies say their adult weight-loss BMI thresholds are not based on clinical data and are provided in the product offering to allow a subset of patients to obtain the medications.

Here is the whole benchmark in one screen.

Source: The RX Index GLP-1 Prior Authorization Public-Policy Matrix, version 2026-07-31. Sample definition: 20 adult Wegovy/Zepbound chronic weight-management pathways in 10 public documents. This is not 20 independent insurers, not an enrollment-weighted national estimate, and not a count of every public template an organization publishes.

The convergence in that table is real. So is the divergence underneath it. Both matter.

What are the GLP-1 prior authorization requirements by insurer in 2026?

There is no reliable one-rule-per-insurer answer. The requirement governing a prescription is set by the combination of plan, pharmacy benefit manager, formulary, drug, formulation, indication, policy scope, and effective date. Public policies are accurate reference points for the plans they cover, but a company’s name alone does not tell you which policy controls.

That is not a hedge. It is what the documents themselves say.

UnitedHealthcare Program 2026 P 1114-21, effective July 1, 2026, calls itself an optional program for clients or businesses that elected to cover weight-loss products with prior authorization. It also contains state-specific provisions. Cigna’s current policies say the customer’s benefit plan document can differ from the standard policy and controls in a conflict. Aetna 6450-C calls itself a partial, general description of plan benefits rather than a contract. CVS Caremark’s public criteria likewise operate inside a member’s plan and formulary rather than as one universal Caremark benefit.

The 20 coded pathways break down like this:

Source: The RX Index coding of Cigna IP0206, BEO005, BEO006 and CNF684; UnitedHealthcare Program 2026 P 1114-21; CVS Caremark 4774-C and 6192-C; Aetna 6450-C; and FEP 5.99.030 and 5.99.031. Version 2026-07-31.

The UHC BMI-40 number is real, but it is not the general UnitedHealthcare rule. It appears in the North Dakota fully insured EHB section for small-group and individual plans. The general commercial pathway in the same document uses BMI ≥30, or BMI ≥27 with a weight-related comorbidity. Both statements are true of a UnitedHealthcare document. Neither should be stated as the company’s one nationwide requirement.

Terms, defined once. Prior authorization is a plan requirement that approval be obtained before the plan will pay under the applicable benefit. Formulary is the plan’s covered-drug list and coverage position. Nonformulary means the drug is not on that list; an exception process may exist. Step therapy requires trying specified treatments first. Pharmacy benefit manager (PBM) is the company administering the drug benefit, which can differ from the insurer on the card. Plan sponsor is the employer or organization that chose the benefit design.

Why does the same insurer publish more than one BMI threshold?

Because the policy being applied can be a different benefit product, formulary program, or exclusion override. Cigna currently publishes BMI-30, BMI-32, and BMI-35 policy families for adult weight-management GLP-1 coverage. UnitedHealthcare places BMI-30 and BMI-40 pathways in different sections of one document.

Cigna’s current public identifiers matter. Older indexed copies can still appear under IP0621 and IP0739. The documents verified for this dataset are BEO005 and BEO006, both effective June 1, 2026.

We read the three current Cigna threshold policies end to end. Here is what changes and what does not.

Source: Cigna Drug Coverage Policies IP0206, BEO005, and BEO006, each effective June 1, 2026. Retrieved and coded by The RX Index on July 31, 2026.

Both BEO005 and BEO006 describe the adult entry thresholds as product-offering parameters rather than clinically derived cutoffs. BEO005 adds something else that no other pathway in this sample states: four weigh-ins and four app engagements every month through a designated lifestyle vendor.

What this looks like for one patient

Same person. Same insurer. Same day. Three answers.

Adult, age 44, BMI 31, hypertension as one qualifying comorbidity, no prior GLP-1 use, and a documented four-month diet-and-behavior program, requesting Zepbound:

Source: The RX Index worked example applying the published BMI, comorbidity-count, and pre-treatment lifestyle conditions in Cigna IP0206, BEO005, and BEO006. It does not assume formulary placement, preferred-product compliance, benefit eligibility, or final approval.

Nothing in the stated clinical profile changes across the three rows. The policy changes.

That does not prove why any employer selected a particular option. It does prove that “Cigna’s BMI requirement” is not one number.

What do the 2026 GLP-1 prior authorization data show — and what do they not show?

The sample shows complete convergence on four coded elements: an adult BMI gate, a lifestyle or weight-management condition, a 5% continuation threshold, and a 12-month renewal period. It also shows real divergence in entry thresholds, fixed lifestyle periods, medication steps, stable-dose requirements, and initial approval lengths. These are unweighted pathway counts, not estimates of how many insured people face each rule.

What the benchmark supports:

• Every one of the 20 coded pathways contained an adult BMI gate.
• Every pathway required lifestyle modification, program participation, or a documented pre-treatment program.
• Every pathway required at least 5% loss from baseline body weight or maintenance of an initial 5% loss for continuation.
• Every coded renewal period was 12 months.
• Fourteen pathways specified a fixed period before treatment: three months in the eight Cigna rows and six months in the six CVS Caremark and Aetna rows.
• Six pathways required at least three months at a stable maintenance dose before continuation.
• One pathway — FEP Zepbound — explicitly required inadequate response, intolerance, or contraindication to two oral weight-management medications.
• Initial approvals ranged from five to eight months.

What the benchmark does not support:

• The share of Americans subject to any one rule. The rows are not enrollment-weighted.
• Approval rates, denial rates, appeal results, or decision times. We coded written criteria, not adjudications.
• A conclusion that the five organizations or programs are statistically independent. CVS Caremark administers pharmacy benefits for Aetna products, and several Cigna rows are parallel policy families from one issuer.
• A conclusion that a drug is on a member’s formulary. Clinical criteria and formulary placement are separate.
• A conclusion that every public Cigna template was counted. We deliberately excluded near-duplicate templates that repeat an already included threshold structure.
• A determination about a particular member’s coverage.

Where a table says “not stated,” it means the requirement did not appear in the coded public branch. It does not mean the requirement cannot exist in a plan document, formulary rule, state mandate, preferred-product program, or member-specific benefit.

How do Wegovy and Zepbound requirements compare across insurers and plans?

The concepts repeat; the numbers do not. Aetna’s sampled policy uses BMI 35 with six months of prior program participation and no lower-BMI adult route. UnitedHealthcare’s general pathway uses BMI 30 or BMI 27 with a comorbidity and no fixed prior period. CVS Caremark’s public standard criteria use six months. The FEP Zepbound pathway is the only row that explicitly requires two oral weight-management drugs first.

Source: The linked Cigna, UnitedHealthcare, CVS Caremark, Aetna, and FEP issuer documents. Dataset version 2026-07-31. “Not stated” means absent from the coded public branch, not necessarily absent from a member’s plan.

Three details in that table change the answer in practice.

One drug, two clocks. CVS Caremark 4774-C grants seven months initially for Wegovy injection and six months for Wegovy tablet. Aetna 6450-C grants eight months for Wegovy injection/HD and six for the tablet. A drug name without a formulation is not enough to state the approval period.

“Lifestyle requirement” is not one requirement. UnitedHealthcare requires concurrent lifestyle modification and states no fixed prior period in the coded branch. Cigna requires three months before treatment. CVS Caremark and Aetna require six months of a comprehensive program with continuing follow-up. FEP requires program participation without stating a fixed prior duration.

Medication step therapy is not universal. FEP Zepbound explicitly requires two oral weight-management medications and a preferred-product trial unless an exception applies. No equivalent two-oral-drug step appears in the other 19 coded public branches. That does not rule out separate plan-specific steps.

What is identical across the 20 pathways?

Four elements were present in every coded pathway: an adult BMI gate, a lifestyle or weight-management condition, at least 5% loss or maintenance for continuation, and a 12-month renewal period. Three other requirements were common but not universal: a fixed pre-treatment period, explicit use of pre-treatment BMI, and three months at a stable maintenance dose.

Source: The RX Index GLP-1 Prior Authorization Public-Policy Matrix, version 2026-07-31.

The invariants are useful. The limits are just as useful. “Prepare for BMI documentation, lifestyle documentation, and a renewal weight” is supported by all 20 rows. “Every plan requires six months,” “every plan uses starting BMI,” and “every plan requires step therapy” are not.

How long is a GLP-1 prior authorization approved for?

Initial Wegovy and Zepbound approvals in the benchmark ranged from five to eight months. Two pathways were five months, six were six months, one was seven months, and eleven were eight months. Every renewal period was 12 months.

Source: The RX Index GLP-1 Prior Authorization Public-Policy Matrix, version 2026-07-31.

The spread is not cosmetic. UHC grants five months initially for Wegovy. Cigna grants eight months in each of the four policy families included here. That is a three-month difference before the first continuation review.

The documents state the durations. They do not provide one shared explanation for why each organization chose its number, so this dataset does not assign one.

What must be shown for a GLP-1 renewal?

All 20 pathways required at least 5% loss from baseline body weight or maintenance of an initial 5% loss, and every coded renewal lasted 12 months. Six pathways added at least three months at a stable maintenance dose: all three CVS Caremark rows and all three Aetna rows.

The word maintenance matters. CVS Caremark, Aetna, and FEP explicitly allow continuation when the patient has maintained an initial 5% loss rather than requiring a fresh 5% reduction during every authorization cycle.

The documents also separate entry thresholds from response thresholds. Cigna IP0206 says sustained loss of at least 5% may produce clinically meaningful health benefits. BEO005 and BEO006 separately say their adult entry BMI thresholds are not based on clinical data. The documents themselves therefore treat “Who enters?” and “Who is responding?” as different questions.

UnitedHealthcare’s wider weight-loss policy shows that the response threshold is drug-specific outside this Wegovy/Zepbound benchmark: it uses 4% for Saxenda, 5% for Wegovy and Zepbound, and 3% for Qsymia. That is why the 5% result should be stated as a Wegovy/Zepbound finding, not as a universal rule for every anti-obesity medication.

Does weight already lost count when BMI is reviewed?

In 14 of 20 pathways, the public policy explicitly ties the initiation BMI to the value before GLP-1 therapy or at the start of any weight-loss drug therapy. The four UnitedHealthcare and two FEP initiation branches do not state the same universal instruction. “Every insurer uses starting BMI” is therefore too broad.

Source: The linked Cigna, CVS Caremark, Aetna, UnitedHealthcare, and FEP policy branches. Dataset version 2026-07-31.

For the 14 explicit pathways, the practical rule is clear: preserve the pre-treatment height, weight, BMI, therapy start date, and any qualifying comorbidity record. A patient whose BMI fell after treatment is not reclassified as though treatment never happened under those documents.

CMS uses the same logic in the separate Medicare GLP-1 Bridge. Its provider guidance gives an example of a beneficiary who began therapy at BMI 37 and is at BMI 34 during a July 2026 request; the provider attests to the BMI at therapy initiation.

For UnitedHealthcare and FEP, the public continuation criteria still measure loss from baseline body weight, but their public initiation language does not contain the same pre-treatment-BMI instruction. The exact governing plan document should supply the answer.

Do Ozempic and Mounjaro follow the same prior authorization rules?

Usually not. Wegovy and Zepbound chronic weight-management branches are built around BMI, lifestyle treatment, and continuation weight loss. Ozempic and Mounjaro diabetes branches are built around type 2 diabetes, clinical records or claims evidence, and product-specific eligibility. Coverage of one establishes nothing about the other.

Source: The linked UnitedHealthcare and Cigna diabetes GLP-1 policies. Retrieved July 31, 2026.

The separation is explicit inside CVS Caremark 4774-C. Its Wegovy cardiovascular-risk pathway requires that the patient not have type 2 diabetes and points to Ozempic as the cardiovascular-risk product for adults with type 2 diabetes and established cardiovascular disease.

This is why “Ozempic was covered but Wegovy was denied” is not automatically a contradiction. It can be two different indications, two different products, two different benefit categories, and two different policies doing exactly what they say.

What other GLP-1 indication pathways can change the answer?

Weight management is not the only published pathway for these drugs. Separate branches exist for Zepbound in moderate-to-severe obstructive sleep apnea, Wegovy in cardiovascular-risk reduction, and Wegovy injection in noncirrhotic MASH with F2–F3 fibrosis. Those branches use different evidence and cannot be folded into the 20-row weight-management count.

Source: The linked CVS Caremark, Cigna, and UnitedHealthcare issuer policies. Retrieved July 31, 2026.

A separate indication branch is evidence that the issuer published separate criteria. It is not evidence that every member has the corresponding benefit. Formulary position, benefit exclusions, product scope, and the governing plan still control.

The distinction can be large. UHC’s current policy says there is no BMI requirement for its Wegovy MASH branch. Cigna’s Zepbound OSA branch, by contrast, uses baseline BMI 30 and an apnea-hypopnea index of at least 15, then requires at least 10% loss after one year plus stability in OSA signs or symptoms. Neither rule belongs in a generic “weight-loss BMI requirement.”

Why can the same insurer cover one GLP-1 and exclude another?

Because clinical criteria and formulary status answer different questions. A policy can describe the clinical conditions used in a review while the formulary lists the drug as nonformulary. Meeting clinical criteria does not put a drug on the formulary, and formulary placement does not remove prior authorization.

The cleanest public example is inside Aetna.

Aetna’s May 2026 Advanced Control Plan formulary lists Wegovy as a preferred brand subject to prior authorization and lists Zepbound as nonformulary. Aetna 6450-C separately publishes adult clinical criteria for Wegovy and Zepbound. Both documents can be current because they answer different questions.

This is an example from one named formulary, not an Aetna-wide statement. The sampled formulary and 6450-C are separate artifacts, and the page does not claim that every member using one is governed by the other.

Source: The RX Index synthesis of the sampled Aetna formulary and the governing-plan language in the issuer policies reviewed. Version 2026-07-31.

Cigna BEO005 and BEO006 show another layer. They are benefit-exclusion override policies: narrower pathways designed to authorize specified coverage where the base benefit otherwise excludes weight-loss drugs. That is how one issuer can publish different thresholds without one document canceling the others.

Why is there no one nationwide rule per insurer?

Because several names people search are not one national rulebook. Some are associations of independent companies. Some are PBMs administering different formularies for different employers. Some are insurers whose weight-loss policy applies only when the client bought the benefit.

Source: CarelonRx drug-list architecture, BCBS company structure, Humana drug-list tools, Kaiser formulary lookup, and the Cigna, CVS Caremark, Aetna, and UHC documents cited in this page. Retrieved July 31, 2026.

The insurer name is the first lookup field, not the answer.

What changes under Medicare and Medicaid?

Medicare and Medicaid should not be inserted into the commercial 20-row benchmark. The Medicare GLP-1 Bridge is a separate federal demonstration with a central prior-authorization route. Medicaid obesity coverage is state-specific and optional under federal drug-coverage rules.

Medicare GLP-1 Bridge

The Medicare GLP-1 Bridge runs from July 1, 2026, through December 31, 2027. CMS uses a single central processor for prior authorization, claims adjudication, and pharmacy payment. The copay is $50 per eligible 30-day supply.

The Bridge operates outside the Part D benefit payment flow. CMS states that the Part D deductible does not apply, the $50 does not count toward true out-of-pocket costs, and the Part D low-income subsidy does not reduce it.

Source: CMS Medicare GLP-1 Bridge provider guidance, last modified July 13, 2026.

Eligible weight-management products listed by CMS are Foundayo, all Wegovy formulations, and Zepbound KwikPen. The single-dose Zepbound vial and single-dose pen are not included in the Bridge.

CMS assesses the clinical criteria at the time GLP-1 therapy was initiated. Type 2 diabetes, moderate-to-severe obstructive sleep apnea, and noncirrhotic MASH remain Part D-covered indications rather than Bridge indications. CMS separately says that a prescription written to reduce the risk of major adverse cardiovascular events should be routed to the Part D plan, even where the Bridge’s BMI-27 criteria overlap. A beneficiary using a GLP-1 for a Part D-covered indication continues through the Part D plan.

The Medicare Bridge is excluded from the 20-row insurer benchmark because it is a federal demonstration with its own eligibility structure, products, payment route, and indication rules.

Medicaid

Under 42 U.S.C. § 1396r-8(d)(2)(A), state Medicaid programs may exclude or restrict agents when used for weight loss, making obesity coverage a state decision. KFF counted 13 state fee-for-service programs covering GLP-1s for obesity in January 2026, down from 16 in October 2025. The RX Index’s separate GLP-1 Medicaid Coverage by State tracker verified 11 state programs with current adult obesity coverage as of July 10, 2026, after Utah’s pilot ended June 30 and Massachusetts ended coverage July 1.

The state-level source record is maintained in that tracker and is not duplicated into this commercial-policy denominator.

Self-funded employer plans

A self-funded employer can decide whether anti-obesity medications are included at all and can adopt, modify, or decline a PBM’s standard criteria. That is why “CVS Caremark requires X” is often too broad. Caremark can publish a standard policy while different plan sponsors use different formularies and benefits.

Why does this data matter now?

The pool of people who may meet clinical BMI criteria is much larger than the pool whose employer plans cover GLP-1s for weight loss. The resulting gap is where benefit exclusions, formularies, prior authorization, and continuation rules do their work.

Source: Peterson-KFF Health System Tracker, KFF 2025 Employer Health Benefits Survey, KFF Medicaid coverage analysis, and The RX Index state tracker. Each figure carries its own as-of date.

The documents also move quickly.

• UnitedHealthcare’s current weight-loss policy records six Pharmacy and Therapeutics approvals from March 2025 through April 2026.
• Aetna’s sampled Advanced Control formulary says it is updated during the first week of each month and that older versions cease to be effective.
• Cigna’s current BMI-32 and BMI-35 documents are BEO005 and BEO006, effective June 1, 2026; older identifiers can remain visible in indexes and saved copies.

An undated statement of “what an insurer requires” can be accurate when written and wrong when read. That is why the source version, effective date, retrieval date, and change history sit next to the data rather than in a hidden note.

How to build your dataset query: the nine-step sequence

Start with the plan, not the carrier logo. The reliable sequence is: identify the exact plan, identify the pharmacy-benefit administrator, confirm that the benefit exists, check the exact drug and formulation on the current formulary, then open the applicable clinical criteria and verify the policy date and indication.

1. Read the exact plan name from the card, Summary Plan Description, Evidence of Coverage, or pharmacy-benefit documents.
2. Identify the pharmacy benefit administrator. It may differ from the medical insurer.
3. Confirm whether weight-management drugs are included in the benefit. If they are excluded, clinical criteria may never be reached.
4. Search the current formulary for the exact drug and formulation. Wegovy injection and tablet can have different approval periods.
5. Record the coverage position: preferred, nonpreferred, nonformulary, PA, step therapy, quantity limit, or benefit exclusion.
6. Open the linked criteria and verify the effective date or version.
7. Match the prescription to the right indication branch: weight management, cardiovascular risk, OSA, MASH, or type 2 diabetes.
8. Preserve baseline records where the policy uses pre-treatment BMI or baseline body weight.
9. Use the governing plan document when it conflicts with a general public policy. Cigna and Aetna say this directly.

This is a map of how the documents fit together. It is not a coverage determination and does not replace the plan’s current records or the prescriber’s clinical judgment.

How was the GLP-1 insurer-policy dataset built?

The dataset was assembled from public issuer documents, normalized into one row structure, and checked a second time against each source. One row represents one named drug’s adult chronic weight-management pathway within one policy document and plan scope; formulations share a row only when every coded adult criterion and approval duration matches. The benchmark separates pathways when a different formulation, plan section, or policy changes a coded field that matters.

What counted as a source

A pathway entered the benchmark only when:

• the document came from the insurer, PBM, program, or regulator itself;
• it was publicly accessible without a member login;
• the adult chronic weight-management pathway for Wegovy or Zepbound could be isolated;
• initiation and continuation rules could be distinguished;
• the policy scope, version, effective date, or current public status could be recorded.

We excluded manufacturer access guides, provider blogs, forum accounts, screenshots without a reproducible public source, pediatric-only pathways, diabetes pathways, cardiovascular-risk pathways, MASH pathways, obstructive-sleep-apnea pathways, Medicaid state policies, and the Medicare GLP-1 Bridge from the 20-row denominator. Those topics are handled separately above.

The unit of analysis

One drug-policy pathway is one named drug’s adult chronic weight-management branch inside one public document and plan scope. Formulations share a row only when every coded adult criterion and approval duration matches.

We combined formulations only when their coded adult initiation criteria, continuation criteria, and approval periods matched. That is why:

• Cigna’s Wegovy injection, HD injection, and tablet can share one row within a policy;
• UnitedHealthcare’s adult Wegovy injection and tablet branches can share one row within a plan scope;
• CVS Caremark’s Wegovy injection and tablet are split because the injection receives seven months initially and the tablet receives six;
• Aetna’s Wegovy injection/HD branch and tablet branch are split for the same reason;
• UHC’s general pathway and North Dakota EHB pathway are separate rows even though they live in one PDF, because their BMI gates differ.

The analytic population is adults age 18 and older. Policies that also contain pediatric or older-adolescent criteria remain outside these adult rows.

How we prevented template volume from becoming the result

Cigna publishes more parallel public templates than the other organizations in this benchmark. Counting every near-identical template would make the denominator partly a measure of how many documents Cigna publishes.

We therefore included:

• one current Cigna document for each distinct threshold family: IP0206 at BMI 30, BEO005 at BMI 32, and BEO006 at BMI 35;
• CNF684 because it is a separate National Formulary PA policy with a separate stated scope.

We disclosed but did not count current sibling templates such as CNF908 and CNF950, which repeat included BMI-32 and BMI-35 structures. This rule was set before recalculating the summary statistics.

Coding rules

• Preserve the policy’s operative meaning rather than turning it into a broader insurer claim.
• Use not stated when a requirement is absent from the coded branch. Never turn that into not required.
• Keep a fixed pre-treatment period separate from concurrent lifestyle modification.
• Keep clinical criteria separate from formulary status.
• Keep the general UHC pathway separate from the North Dakota EHB section.
• Split formulations when approval duration or another coded adult criterion differs.
• Record both the original wording and a normalized value in the dataset.
• Record a source title, URL, policy identifier, effective or revision date, retrieval date, and source section.
• Recalculate every count from the frozen CSV rather than editing headline figures by hand.

Verification sequence

Each source was retrieved from its issuer, coded into the matrix, and checked again against the original document. The 20-row CSV was then frozen as version 2026-07-31, and the summary counts were generated from that file. The visible “Last verified” date changes only after the document links, row values, calculations, and page copy have been checked together.

Limitations

How to cite this page

Frequently asked questions

Primary-source ledger

Source: Each linked issuing organization. Retrieval date: July 31, 2026.

Additional public documents used for interpretation

• Aetna May 2026 Advanced Control Plan formulary
• Cigna National Formulary diabetes GLP-1 policy
• UnitedHealthcare commercial diabetes GLP-1 policy
• CMS Medicare GLP-1 Bridge overview
• Cigna CNF908, disclosed near-duplicate BMI-32 template
• Cigna CNF950, disclosed near-duplicate BMI-35 template
• CarelonRx drug lists
• Blue Cross Blue Shield company structure
• Humana drug-list tools
• Kaiser Permanente drug-formulary lookup

Change log

Source: The RX Index dataset release record.

Related research

• GLP-1 Medicaid Coverage by State State-level fee-for-service and managed-care coverage
• BALANCE Model Medicaid Participating States 51-jurisdiction public-record tracker
• Medicare GLP-1 Bridge Tracker Drugs, cost, eligibility, and routes
• GLP-1 Price & Access Tracker Verified pricing across access routes
• GLP-1 Statistics 2026 Usage, cost, and coverage data
• The RX Index Research Hub All published datasets and trackers

The RX Index Research publishes original, primary-sourced datasets on GLP-1 access and coverage. It is an independent research and reference resource. No sponsorship, product placement, affiliate links, or provider promotion appears on this page.